ReproCell Inc
F:6RC

Watchlist Manager
ReproCell Inc Logo
ReproCell Inc
F:6RC
Watchlist
Price: 0.595 EUR 6.25%
Market Cap: 55.5m EUR

ReproCell Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ReproCell Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
ReproCell Inc
TSE:4978
Net Income (Common)
-ÂĄ278.9m
CAGR 3-Years
3%
CAGR 5-Years
22%
CAGR 10-Years
9%
3
3-D Matrix Ltd
TSE:7777
Net Income (Common)
ÂĄ6.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Net Income (Common)
-ÂĄ701.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-5%
PeptiDream Inc
TSE:4587
Net Income (Common)
-ÂĄ5.8B
CAGR 3-Years
-85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Net Income (Common)
-ÂĄ6.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Net Income (Common)
-ÂĄ644.3m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ReproCell Inc
Glance View

Market Cap
56.3m EUR
Industry
Biotechnology

ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

6RC Intrinsic Value
0.432 EUR
Overvaluation 27%
Intrinsic Value
Price

See Also

What is ReproCell Inc's Net Income (Common)?
Net Income (Common)
-278.9m JPY

Based on the financial report for Sep 30, 2025, ReproCell Inc's Net Income (Common) amounts to -278.9m JPY.

What is ReproCell Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
9%

Over the last year, the Net Income (Common) growth was -42%. The average annual Net Income (Common) growth rates for ReproCell Inc have been 3% over the past three years , 22% over the past five years , and 9% over the past ten years .

Back to Top